BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aldea M, Orillard E, Mansi L, Marabelle A, Scotte F, Lambotte O, Michot J. How to manage patients with corticosteroids in oncology in the era of immunotherapy? European Journal of Cancer 2020;141:239-51. [DOI: 10.1016/j.ejca.2020.09.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Han X, Zang D, Liu D, Chen J. The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application. Front Immunol 2022;13:988849. [DOI: 10.3389/fimmu.2022.988849] [Reference Citation Analysis]
2 Mispelbaum R, Hattenhauer ST, Brossart P, Heine A. Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors. Front Immunol 2022;13:976011. [DOI: 10.3389/fimmu.2022.976011] [Reference Citation Analysis]
3 Bernhardt D, König L, Grosu AL, Rieken S, Krieg SM, Wick W, Wiestler B, Schmidt-Graf F, Sahm F, Gempt J, Meyer B, Krause BJ, Petersen C, Fietkau R, Thomas M, Giordano F, Wittig-Sauerwein A, Debus J, Tabatabai G, Hau P, Steinbach J, Combs SE; Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment. Strahlenther Onkol 2022. [PMID: 36038670 DOI: 10.1007/s00066-022-01973-8] [Reference Citation Analysis]
4 Feola T, Carbonara F, Verrico M, Di Crescenzo RM, Gianno F, Colonnese C, Arcella A, de Alcubierre D, Tomao S, Esposito V, Giangaspero F, Minniti G, Jaffrain-rea M. Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art. Cancers 2022;14:4093. [DOI: 10.3390/cancers14174093] [Reference Citation Analysis]
5 Liu C, Li C. Clinical Features and Risk Factors of Severe Pneumonia in Children With Acute Lymphoblastic Leukemia. Front Pediatr 2022;10:813638. [DOI: 10.3389/fped.2022.813638] [Reference Citation Analysis]
6 Yennurajalingam S, Bruera E. Do Patients Benefit from a Trial of Corticosteroids at the End of Life? Curr Treat Options Oncol 2022. [PMID: 35362799 DOI: 10.1007/s11864-022-00977-x] [Reference Citation Analysis]
7 Kalfeist L, Galland L, Ledys F, Ghiringhelli F, Limagne E, Ladoire S. Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. Cells 2022;11:770. [PMID: 35269392 DOI: 10.3390/cells11050770] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Fediw M, Lau K. Novel Cancer Therapeutics and Implications for Rehabilitation. Curr Phys Med Rehabil Rep 2021;9:224-9. [DOI: 10.1007/s40141-021-00323-6] [Reference Citation Analysis]
9 Montisci A, Vietri MT, Palmieri V, Sala S, Donatelli F, Napoli C. Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. Cancers (Basel) 2021;13:4797. [PMID: 34638281 DOI: 10.3390/cancers13194797] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
10 Paderi A, Gambale E, Botteri C, Giorgione R, Lavacchi D, Brugia M, Mazzoni F, Giommoni E, Bormioli S, Amedei A, Pillozzi S, Matucci Cerinic M, Antonuzzo L. Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. Molecules 2021;26:5789. [PMID: 34641331 DOI: 10.3390/molecules26195789] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Firer MA, Shapira MY, Luboshits G. The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma. Cancers (Basel) 2021;13:4090. [PMID: 34439244 DOI: 10.3390/cancers13164090] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 2021;32:994-1004. [PMID: 34219000 DOI: 10.1016/j.annonc.2021.05.801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 117] [Article Influence: 4.0] [Reference Citation Analysis]
13 Zheng JY, Mixon AC, McLarney MD. Safety, Precautions, and Modalities in Cancer Rehabilitation: an Updated Review. Curr Phys Med Rehabil Rep 2021;:1-12. [PMID: 34178432 DOI: 10.1007/s40141-021-00312-9] [Reference Citation Analysis]
14 El Hazzaz R, Kfoury M, Lavaud P, Marabelle A, Champiat S, Mellas N, Besse B, Massard C, Geraud A. [Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors]. Bull Cancer 2021;108:635-42. [PMID: 33888298 DOI: 10.1016/j.bulcan.2021.01.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]